Stavzor

Migraine, Acute Coryza, Behcet Syndrome + 4 more
Treatment
20 Active Studies for Stavzor

What is Stavzor

Valproic acidThe Generic name of this drug
Treatment SummaryValproic acid, also known as valproate, is a medication that was first used in 1881. It was initially used as an organic solvent in industry and pharmaceutical manufacturing. In 1963, researchers found that it had anticonvulsant properties. Valproic acid was approved by the FDA in 1978 under the trade name Depakene. Today, it is commonly used to treat seizures and is also being studied for its potential anti-cancer effects.
Depakeneis the brand name
image of different drug pills on a surface
Stavzor Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Depakene
Valproic acid
1978
481

Effectiveness

How Stavzor Affects PatientsValproate is used to help control complex partial seizures, migraines, and bipolar mania. It is thought to work by increasing the amount of inhibition (“calming down”) in the brain. Valproate may also help protect the brain from damage and degeneration caused by these conditions. However, it can be toxic to the liver and can cause birth defects. A small study has suggested that Valproate might help fight HIV, but a larger study did not find a significant effect. The FDA has warned that Valproate might cause HIV to become active again.
How Stavzor works in the bodyValproate works on multiple pathways in the body to help treat epilepsy, migraine headaches, and bipolar disorder. It increases GABAergic neurotransmission, which is an inhibitory neurotransmitter, and suppresses voltage-gated sodium channels. It also affects the extracellular signal-related kinase pathway, increasing expression of proteins that promote neural plasticity. Valproate also inhibits myo-inosital-1-phophate synthetase, reducing de novo synthesis of inositol and decreasing protein kinase C proteins, which are associated with bipolar disorder. Additionally, it affects fatty acid metabolism, which changes the action potential

When to interrupt dosage

The suggested measure of Stavzor depends on the diagnosed situation, including Seizures, Seizure, Absence and Complex Partial Seizures. Dosage fluctuates as per the method of delivery (e.g. Injection, solution - Intravenous or Capsule, delayed release) featured in the table beneath.
Condition
Dosage
Administration
Mental Depression
, 250.0 mg, 125.0 mg, 500.0 mg, 250.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 500.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule, Capsule - Oral, Solution, Solution - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Capsule, liquid filled - Oral, Capsule, liquid filled, Tablet, delayed release particles, Tablet, delayed release particles - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Injection, Injection - Intravenous, Syrup, Syrup - Oral, Liquid, Liquid - Intravenous, Capsule, Delayed Release - Oral, Capsule, Delayed Release
Seizures
, 250.0 mg, 125.0 mg, 500.0 mg, 250.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 500.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule, Capsule - Oral, Solution, Solution - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Capsule, liquid filled - Oral, Capsule, liquid filled, Tablet, delayed release particles, Tablet, delayed release particles - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Injection, Injection - Intravenous, Syrup, Syrup - Oral, Liquid, Liquid - Intravenous, Capsule, Delayed Release - Oral, Capsule, Delayed Release
Migraine
, 250.0 mg, 125.0 mg, 500.0 mg, 250.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 500.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule, Capsule - Oral, Solution, Solution - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Capsule, liquid filled - Oral, Capsule, liquid filled, Tablet, delayed release particles, Tablet, delayed release particles - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Injection, Injection - Intravenous, Syrup, Syrup - Oral, Liquid, Liquid - Intravenous, Capsule, Delayed Release - Oral, Capsule, Delayed Release
Acute Coryza
, 250.0 mg, 125.0 mg, 500.0 mg, 250.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 500.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule, Capsule - Oral, Solution, Solution - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Capsule, liquid filled - Oral, Capsule, liquid filled, Tablet, delayed release particles, Tablet, delayed release particles - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Injection, Injection - Intravenous, Syrup, Syrup - Oral, Liquid, Liquid - Intravenous, Capsule, Delayed Release - Oral, Capsule, Delayed Release
Behcet Syndrome
, 250.0 mg, 125.0 mg, 500.0 mg, 250.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 500.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule, Capsule - Oral, Solution, Solution - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Capsule, liquid filled - Oral, Capsule, liquid filled, Tablet, delayed release particles, Tablet, delayed release particles - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Injection, Injection - Intravenous, Syrup, Syrup - Oral, Liquid, Liquid - Intravenous, Capsule, Delayed Release - Oral, Capsule, Delayed Release
Epilepsy
, 250.0 mg, 125.0 mg, 500.0 mg, 250.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 500.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule, Capsule - Oral, Solution, Solution - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Capsule, liquid filled - Oral, Capsule, liquid filled, Tablet, delayed release particles, Tablet, delayed release particles - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Injection, Injection - Intravenous, Syrup, Syrup - Oral, Liquid, Liquid - Intravenous, Capsule, Delayed Release - Oral, Capsule, Delayed Release
Seizures
, 250.0 mg, 125.0 mg, 500.0 mg, 250.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 500.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule, Capsule - Oral, Solution, Solution - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Capsule, liquid filled - Oral, Capsule, liquid filled, Tablet, delayed release particles, Tablet, delayed release particles - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Injection, Injection - Intravenous, Syrup, Syrup - Oral, Liquid, Liquid - Intravenous, Capsule, Delayed Release - Oral, Capsule, Delayed Release

Warnings

Stavzor has five contraindications and should not be consumed while encountering any of the conditions provided in the following table.Stavzor Contraindications
Condition
Risk Level
Notes
Mitochondrial Diseases
Do Not Combine
Liver Failure
Do Not Combine
Disease
Do Not Combine
Liver Diseases
Do Not Combine
Enzymes
Do Not Combine
There are 20 known major drug interactions with Stavzor.
Common Stavzor Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The metabolism of Abemaciclib can be decreased when combined with Valproic acid.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be decreased when combined with Valproic acid.
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Valproic acid.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Valproic acid.
Amiodarone
Major
The metabolism of Amiodarone can be decreased when combined with Valproic acid.
Stavzor Toxicity & Overdose RiskThe toxic dose of Valproate in mice is 1098mg/kg and 670mg/kg in rats. Overdosing on Valproate can lead to drowsiness, heart block, coma, and high salt levels in the blood. In severe cases, death can occur, however patients have survived with levels of Valproate as high as 2120 mcg/mL. Hemodialysis can be used to remove the unbound fraction of the drug from the body. Valproate use during pregnancy is linked to an increased risk of neural tube defects and other birth defects, as well as an
image of a doctor in a lab doing drug, clinical research

Stavzor Novel Uses: Which Conditions Have a Clinical Trial Featuring Stavzor?

65 active trials are being conducted to assess the potential of Stavzor in providing relief for Migraine, Complex Partial Seizures and Acute Coryza.
Condition
Clinical Trials
Trial Phases
Migraine
53 Actively Recruiting
Phase 4, Not Applicable, Phase 2, Phase 1, Phase 3, Early Phase 1
Seizures
0 Actively Recruiting
Seizures
0 Actively Recruiting
Acute Coryza
1 Actively Recruiting
Not Applicable
Behcet Syndrome
1 Actively Recruiting
Not Applicable
Epilepsy
0 Actively Recruiting
Mental Depression
1 Actively Recruiting
Not Applicable

Stavzor Reviews: What are patients saying about Stavzor?

5Patient Review
8/17/2012
Stavzor for Bipolar Depression
Stavzor has been a complete game-changer for my husband. He's been taking it for three years now with zero negative side effects, and our home life is so much happier as a result.
5Patient Review
2/23/2012
Stavzor for Mania associated with Bipolar Disorder
This medication has been great for my son. He started taking it 4 weeks ago and it's already up to 2000mg with no side effects. It's effectively managing his manic symptoms.
5Patient Review
10/28/2010
Stavzor for Mania associated with Bipolar Disorder
This is much easier to swallow than Depakote.
4.7Patient Review
1/6/2010
Stavzor for Mania associated with Bipolar Disorder
The Depakote was effective, but the 500mg pills were really tough to swallow. I also gained weight while taking them. When they switched me to the generic brand, it made things worse - the pills smelled terrible. But Stavzor has been a big improvement. These smaller gelcaps are much easier to take and don't make me gag.
4.3Patient Review
1/13/2009
Stavzor for Bipolar Disorder in Remission
I appreciate the effects of this medication. It's helped me to even out my mood and I don't experience the swings as frequently. The only downside is that I've developed a slight rash, and sometimes have indigestion issues.
View All Reviews
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about stavzor

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Stavzor discontinued?

"The Stavzor brand is no longer being sold in the United States. If the FDA has approved generic versions of this product, there may be similar products available from different manufacturers."

Answered by AI

Is valproic acid delayed release?

"Valproic Acid Delayed-Release Capsules are used to treat seizures, prevent migraine headaches, and treat bipolar problems. It may also be given to you for other reasons."

Answered by AI

Clinical Trials for Stavzor

Have you considered Stavzor clinical trials? We made a collection of clinical trials featuring Stavzor, we think they might fit your search criteria.
Have you considered Stavzor clinical trials? We made a collection of clinical trials featuring Stavzor, we think they might fit your search criteria.
Have you considered Stavzor clinical trials? We made a collection of clinical trials featuring Stavzor, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top